
TRAX Stock Forecast & Price Target
TRAX Analyst Ratings
Bulls say
First Tracks is a clinical-stage biotechnology company with a promising drug candidate in its pipeline. Despite the company's sole focus on research and development, its lead drug ANB033 has shown early effectiveness in clinical trials for multiple diseases and has potential for use in treating other inflammatory diseases. While the company faces risks and is also working on two other potential treatments, ANB033 could provide a comprehensive treatment option for patients with celiac disease and eosinophilic esophagitis who have not responded to current options.
Bears say
First Tracks is currently operating in a single reportable segment, focusing solely on research and development activities for immunology therapeutics. While the company's pipeline appears promising, with three differentiated assets in hand and potential across a range of inflammatory diseases, their financials may be impacted by the high research and development costs associated with clinical trials and the need for a strategic partner or non-dilutive capital to advance rosnilimab. Additionally, the late-stage clinical data for their lead candidate, rosnilimab, in rheumatoid arthritis, did not show statistically significant benefits and there are uncertainties surrounding the mechanistic landscape of their other candidates in development. Therefore, the company may face challenges in generating profitable revenue in the near future, making its stock less attractive for investment.
This aggregate rating is based on analysts' research of First Tracks Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TRAX Analyst Forecast & Price Prediction
Start investing in TRAX
Order type
Buy in
Order amount
Est. shares
0 shares